| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Protein-arginine deiminase type-2, PAD-H19, Peptidylarginine deiminase II, Protein-arginine deiminase type II, PADI2, KIAA0994, PDI2 |
| Entrez GeneID | 11240 |
| WB Predicted band size | 75.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PADI2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 557-586 amino acids from the C-terminal region of human PADI2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PADI2抗体的3篇参考文献的简要总结：
---
1. **文献名称**: *"Peptidylarginine deiminase 2 (PADI2) overexpression in breast cancer cells and its role in tumor progression"*
**作者**: Chang X, et al.
**摘要**: 该研究利用特异性PADI2抗体检测乳腺癌细胞系中PADI2的表达，发现其过表达促进肿瘤细胞的侵袭和迁移，可能与表观遗传调控和细胞外基质重塑相关。
---
2. **文献名称**: *"Development of monoclonal antibodies against human PADI2 and their application in autoimmune diseases"*
**作者**: Nakashima K, et al.
**摘要**: 研究团队开发了一种高特异性抗人PADI2单克隆抗体，验证了其在免疫印迹和免疫组化中的有效性，并发现类风湿性关节炎患者滑膜组织中PADI2表达显著上调，提示其参与瓜氨酸化自身抗原的产生。
---
3. **文献名称**: *"PADI2-mediated citrullination in the brain: Implications for neurodegenerative disorders"*
**作者**: Ishigami A, et al.
**摘要**: 通过PADI2抗体进行脑组织染色，研究发现阿尔茨海默病模型中PADI2活性增加，导致tau蛋白异常瓜氨酸化，可能与神经纤维缠结的形成和疾病进展相关。
---
以上文献均涉及PADI2抗体的实验应用，涵盖癌症、自身免疫疾病和神经退行性疾病等领域的研究。
PADI2 (peptidylarginine deiminase 2) is a calcium-dependent enzyme belonging to the peptidylarginine deiminase family, which catalyzes the post-translational conversion of arginine residues to citrulline in proteins. This process, termed citrullination, plays critical roles in various physiological and pathological processes, including epigenetic regulation, inflammation, and autoimmune diseases. PADI2 is widely expressed in multiple tissues, with notable activity in the brain, skeletal muscle, and immune cells. Its involvement in diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), and certain cancers has drawn significant research interest, particularly due to its role in generating citrullinated autoantigens linked to autoimmune responses.
Antibodies targeting PADI2 are essential tools for studying its expression, localization, and function in both normal and disease contexts. These antibodies enable the detection of PADI2 in immunoassays (e.g., Western blot, immunohistochemistry) and facilitate research into its mechanistic contributions to pathologies. For example, in RA, PADI2-mediated citrullination of joint proteins may trigger anti-citrullinated protein antibodies (ACPAs), a hallmark of the disease. In cancer, PADI2 overexpression has been associated with tumor progression via modulation of the tumor microenvironment or immune evasion. However, the specificity and validation of PADI2 antibodies remain crucial, as cross-reactivity with other PADI isoforms (e.g., PADI4) can complicate interpretations. Ongoing studies aim to refine antibody reliability and explore therapeutic strategies targeting PADI2 activity in autoimmune disorders and oncology.
×
